Item |
Total
(n = 331) |
Men group
(n = 241) |
Women group
(n = 70) |
p-value |
Age (year) |
58.8±10.1 |
58.7±10.4 |
59.0±9.2 |
0.846 |
Body mass index (kg/m2) |
27.2±4.2 |
26.6±4.0 |
29.6±5.3 |
< 0.001 |
CR indication |
CABG |
217 (69.8) |
181 (75.1) |
36 (51.4) |
< 0.001 |
PCI |
64 (20.6) |
46 (19.1) |
18 (25.7) |
0.227 |
Valve surgery |
23 (7.4) |
7 (2.9) |
16 (22.9) |
< 0.001 |
Functional class |
|
|
|
|
I |
257 (82.6) |
212 (88.0) |
45 (64.3) |
< 0.001 |
II |
54 (17.4) |
29 (12.0) |
25 (35.7) |
|
Risk stratification |
Mild |
201 (64.6) |
167 (69.3) |
34 (48.6) |
|
Moderate |
82 (26.4) |
57 (23.7) |
25 (35.7) |
0.004 |
Severe |
28 (9.0) |
17 (7.1) |
11 (15.7) |
|
Medications: |
Beta-blockers |
269 (87.1) |
209 (87.1) |
60 (87.0) |
0.978 |
Calcium-blockers |
40 (12.9) |
31 (12.9) |
9 (13.0) |
0.978 |
ACE-inhibitors |
90 (29.1) |
67 (27.9) |
23 (33.3) |
0.383 |
Diuretics |
44 (14.2) |
23 (9.6) |
21 (30.4) |
< 0.001 |
Nitrates |
199 (64.4) |
155 (64.6) |
44 (63.8) |
0.901 |
Anti-hyperlipidemia |
257 (83.2) |
199 (82.9) |
58 (84.1) |
0.823 |
Anti-hyperglycemia |
58 (18.8) |
38 (15.8) |
20 (29.0) |
0.014 |
Antidepressant |
3 (1.0) |
0 (0) |
3 (4.3) |
0.011 |
Data are presented as mean ± SD or n (%)
CR: Cardiac Rehabilitation; CABG: Coronary Artery Bypass Grafting; PCI: Percutaneous Coronary Interventions |
